Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jul 18, 2026

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Clinical experience with an integrated continuous glucose sensor/insulin pump platform: a feasibility study.

John J Mastrototaro¹, Ken W Cooper, Gopi Soundararajan

¹Medtronic Diabetes, Northridge, California 91325, USA.

Advances in Therapy

|December 5, 2006

Summary

Continuous glucose monitoring (CGM) paired with insulin pumps significantly improves glycemic control in type 1 diabetes patients. This integrated system offers a promising advancement for managing diabetes and reducing A1C levels.

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Performance of a Wearable Ring in Controlled Hypoxia: A Prospective Observational Study.

JMIR formative research·2024

Same author

Mobile health: the power of wearables, sensors, and apps to transform clinical trials.

Annals of the New York Academy of Sciences·2016

Same author

Feasibility of an Orthogonal Redundant Sensor incorporating Optical plus Redundant Electrochemical Glucose Sensing.

Journal of diabetes science and technology·2016

Same author

The Transformation of Diabetes Care Through the Use of Person-Centered Data.

Journal of diabetes science and technology·2015

Same author

Model-based sensor-augmented pump therapy.

Journal of diabetes science and technology·2013

Same author

Continuous glucose monitoring considerations for the development of a closed-loop artificial pancreas system.

Journal of diabetes science and technology·2012

Area of Science:

Endocrinology
Biomedical Engineering
Diabetes Technology

Background:

The US Food and Drug Administration recently approved an integrated real-time continuous glucose monitoring (CGM) and insulin pump system.
This approval marks a significant step towards developing a closed-loop insulin delivery system for diabetes management.
Current diabetes care methods struggle to achieve glycemic control targets for many individuals.

Purpose of the Study:

To evaluate the effectiveness of an early prototype integrated real-time CGM and insulin pump system in subjects with type 1 diabetes.
To assess the impact of this combined therapy on glycemic control, specifically A1C levels.
To explore the potential of this technology to revolutionize diabetes care.

Main Methods:

Related Experiment Videos

Last Updated: Jul 18, 2026

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

An observational study involving 20 volunteer subjects with type 1 diabetes.

Subjects used an early prototype of the integrated real-time CGM and insulin pump system for an average of 317 days.

Participants received technical instruction but no additional diabetes management support beyond their usual care.

Main Results:

Subjects achieved a mean A1C reduction of 1.1% (standard deviation, 0.8).
The number of participants achieving an A1C below 7% more than tripled after 3 months of device use.
Individuals with a baseline A1C of 7% or higher had a 67% likelihood of reaching an A1C below 7% by the first follow-up.

Conclusions:

Combined real-time CGM and insulin pump therapy demonstrates potential for improving glycemic control in type 1 diabetes.
This innovative device offers a more effective method for patients to achieve diabetes control targets.
Further development of integrated systems could significantly benefit individuals with diabetes, reducing the risk of long-term complications.